Jazz Pharmaceuticals plc
NASDAQJazz Pharmaceuticals heads into the back half of June with short sellers continuing their retreat and the Street firmly bullish — yet the stock has drifted lower since the last note, raising a quiet question about whether analyst enthusiasm is getting ahead of the price action. The short covering story remains intact, and the numbers have accelerated. Short interest has dropped…
JAZZ cost to borrow surges 126% in one week to 0.38%, signaling rising short-covering pressure as short interest declines 5.9% over the same period.
Jazz Pharmaceuticals heads into the back half of June with short sellers continuing their retreat and the Street firmly bullish — yet the stock has drifted lower since the last note, raising a quiet question about…
Jazz Pharmaceuticals enters mid-June with an unusual combination: short sellers are beating a sustained retreat while analysts are racing to lift their targets — and Bank of America fired the latest shot this…
Snapshot as of 22 Jun 2026
Jazz Pharmaceuticals heads into late May with shorts in full retreat — a month-long covering wave that has cut short interest nearly in half, even as a fresh wave of analyst upgrades pushes price targets well above the…
Jazz Pharmaceuticals just delivered its strongest quarterly beat in years — and the positioning data shows shorts were already getting out of the way before the numbers hit. Q1 2026 revenue came in at $1.07 billion, up…
Jazz Pharmaceuticals heads into its May 6 Q1 earnings report with short sellers meaningfully on the back foot after a sharp squeeze in late April. The short interest story has been the defining positioning move of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for JAZZ — free to start on ORTEX.
Sign up for free →Open JAZZ on ORTEX